BBOT Stock Forecast: Bridgebio Oncology Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Bridgebio Oncology Therapeutics, Inc. is $17. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 22 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Bridgebio Oncology Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (68): Analysts have, on balance, been raising their forecasts.
Momentum (6): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BBOT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BBOT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 11 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | Morgan Stanley | Maintains | Overweight | $13 → $12 |
| 11 Nov 2026 | Piper Sandler | Maintains | Overweight | $21 → $15 |
| 11 Nov 2026 | Wedbush | Maintains | Outperform | $25 → $9.00 |
| 21 Oct 2026 | Morgan Stanley | Maintains | Overweight | $18 → $13 |
| 20 Oct 2026 | Oppenheimer | Maintains | Outperform | $22 → $16 |
| 11 Sept 2026 | JP Morgan | Maintains | Overweight | $25 → $23 |
| 10 Sept 2026 | Leerink Partners | Maintains | Outperform | $39 → $27 |
| 9 Sept 2026 | Canaccord Genuity | Maintains | Buy | $23 → $20 |
| 9 Sept 2026 | Raymond James | Maintains | Outperform | $24 → $22 |
| 9 Sept 2026 | Stifel | Maintains | Buy | $23 → $15 |
| 9 Sept 2026 | Wedbush | Reiterates | Outperform | $25 |
| 14 Aug 2026 | JP Morgan | Maintains | Overweight | $27 → $25 |
| 8 July 2026 | JP Morgan | Initiates | Overweight | $27 |
| 22 June 2026 | Oppenheimer | Assumes | Outperform | $22 |
| 11 May 2026 | Canaccord Genuity | Initiates | Buy | — |
| 6 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Feb 2026 | Stifel | Initiates | Buy | — |
| 9 Jan 2026 | Raymond James | Initiates | Outperform | — |
| 11 Dec 2025 | Wedbush | Reiterates | Outperform | — |
| 5 Dec 2025 | Morgan Stanley | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BBOT.
This page is one stock. Monday covers all of them.
BBOT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BBOT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Bridgebio Oncology Therapeutics, Inc. returned −85.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BBOT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 3.4×
- Price / sales
- —
- Price / book
- 0.5×
- EV / EBITDA
- —
Cheaper than 88% of US stocks
Cheaper than 86% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −46.4%
- Return on assets
- −28.2%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bridgebio Oncology Therapeutics, Inc. has a market value of $145.3M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$182.1M.
Diluted earnings per share, trailing twelve months: −$1,232.83.
Free cash flow in the twelve months to 30 June 2026: −$151.6M.
Trailing P/E: 3.4×.
Bridgebio Oncology Therapeutics, Inc. employs 84 people.
Data provided by Twelve Data
BBOT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BBOT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Bridgebio Oncology Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BBOT
What is the BBOT stock price forecast for 2026-2027?
The median 12-month analyst price target for Bridgebio Oncology Therapeutics, Inc. is $17, with estimates ranging from $9 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BBOT stock a buy right now?
Of the 12 analysts covering Bridgebio Oncology Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bridgebio Oncology Therapeutics, Inc. 22 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BBOT?
As at 21 Nov 2026, Bridgebio Oncology Therapeutics, Inc. ranks 22 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (68 of 100).
Will BBOT stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts is $17, and Ticker Nerd's factor model ranks Bridgebio Oncology Therapeutics, Inc. 22 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BBOT stock forecast for 2030?
No analyst covering Bridgebio Oncology Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BBOT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $50 over the next 12 months.
How has BBOT stock performed over the past year?
Bridgebio Oncology Therapeutics, Inc. returned -85.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Bridgebio Oncology Therapeutics, Inc. do?
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancers driven by RAS and PI3Kα pathway alterations. BridgeBio Oncology Therapeutics designs oral, targeted oncology candidates intended to address some of the most common cancer-driving mutations, with a pipeline centered on RAS-related programs and precision cancer treatment.
About Bridgebio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapies for cancers driven by RAS and PI3Kα pathway alterations. BridgeBio Oncology Therapeutics designs oral, targeted oncology candidates intended to address some of the most common cancer-driving mutations, with a pipeline centered on RAS-related programs and precision cancer treatment. Its current work includes advancing investigational medicines that aim to inhibit KRAS and related signaling mechanisms, supporting the broader shift toward mutation-specific cancer care. Headquartered in South San Francisco, California, BridgeBio Oncology Therapeutics plays a specialized role in the oncology market by concentrating on difficult-to-target molecular pathways that are relevant across multiple solid tumors.
CEO Mr. Eli M. Wallace Ph.D. · 84 employees · United States · https://bbotx.com